| Literature DB >> 34176020 |
Patricia Lindberg-Scharf1, Brunhilde Steinger2, Michael Koller3, Andrea Hofstädter4, Olaf Ortmann5, Jan Kurz2, Jonathan Sasse2, Monika Klinkhammer-Schalke2.
Abstract
PURPOSE: The effectiveness of a pathway with quality of life (QoL) diagnosis and therapy has been already demonstrated in an earlier randomized trial (RCT) in patients with breast cancer. We refined the pathway by developing and evaluating an electronic tool for QoL assessment in routine inpatient and outpatient care.Entities:
Keywords: Breast cancer; Complex intervention; Electronic assessment; Patient-physician communication; Patient-reported outcomes; Quality of life
Mesh:
Year: 2021 PMID: 34176020 PMCID: PMC8550515 DOI: 10.1007/s00520-021-06270-1
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.603
Fig. 1Quality of life (QoL-) profile: woman with primary breast cancer, 49 years, married, one child, working. Prognostic classification pT1b(m), SN0, M0, G1, ER pos, PR pos, HER2 neg; breast-conserving surgical therapy with revision surgery after 1 month followed by radiation and anti-estrogen treatment. Red bar = cutoff for a need for QoL therapy (< 50 points)
Baseline characteristics of participants at study entry
| Age (years) mean (SD) | 50.63 (9.68) |
| Marital status | |
| Married | 35 (63) |
| Unmarried | 10 (18) |
| Divorced | 4 (7) |
| Separated | 2 (4) |
| Widowed | 2 (4) |
| Unknown | 3 (5) |
| Children | |
| Yes | 39 (70) |
| No | 11 (20) |
| Unknown | 6 (11) |
| Employment status | |
| Employed | 30 (54) |
| Retired/not employed | 26 (46) |
| Prognostic stage at diagnosis | |
| UICC 0 | 1 (2) |
| UICC I | 21 (38) |
| UICC II | 27 (48) |
| UICC III | 6 (11) |
| UICC IV | 1 (2) |
| Primary disease | |
| Yes | 54 (96) |
| No | 2 (4) |
| Surgical procedure | |
| Breast conserving therapy | 51 (91) |
| Mastectomy | 5 (9) |
| Estrogen receptor positive | 45 (80) |
| Progesterone receptor positive | 44 (79) |
| HER2 positive | 9 (16) |
| Comorbidities | |
| Cardiovascular | 6 (11) |
| Lung | 5 (9) |
| Kidney | 1 (2) |
| Central nervous system | 2 (4) |
| Neoadjuvant therapy | |
| Chemotherapy | 14 (25) |
| None | 39 (70) |
| Unknown | 3 (5) |
Fig. 2Flow chart
Comparison of rates of patients with a need for QoL therapy at 0 and 6 months after surgery
| Totala | 70% | 63% | .58 |
| Single QoL dimensionsb | |||
| Global QoL | 29% | 22% | .61 |
| Physical functioning | 7% | 5% | 1.00 |
| Role functioning | 34% | 29% | .79 |
| Pain | 32% | 24% | .58 |
| Body image | 12% | 20% | .38 |
| Arm symptoms | 38% | 15% | |
| Emotional functioning | 29% | 34% | .75 |
| Cognitive functioning | 12% | 22% | .29 |
| Fatigue | 34% | 44% | .34 |
| Social functioning | 22% | 25% | 1.00 |
| Financial impact | 8% | 28% | |
aNeed for QoL therapy (QoL < 50 points) in at least one of eleven QoL dimensions of EORTC QLQ-C30, QLQ-BR23
bNeed for QoL therapy (QoL < 50 points) in single QoL dimensions of EORTC QLQ-C30, QLQ-BR23
cAll p values derived from McNemar tests
p values < 0.05 are presented in bold face
Fig. 3Rates of patients with a need for quality of life (QoL) therapy (QoL < 50 points on at least one of ten scales) in the present sample compared with two historical controls of the previous RCT (namely RCT’s intervention and control group) [13] over 12 months; scale “financial functioning” was excluded from the analyzes because this scale was not part of the RCT; rates at 18 and 24 months are not analyzed because these were not assessed in the RCT; χ2 tests: 0 months p = .54, 3 months p = .32, 6 months p = .14, 9 months p = .66, 12 months p = .77
Patient evaluations at 6 and 24 months after surgery: subgroup analyzes of participants whose CP “regularly” versus “rarely or never” discussed QoL-profiles with them
| QoL-profile regularly discussed with CP (%) ( | QoL-profile rarely/never discussed with CP (%) ( | QoL-profile regularly discussed with CP (%) ( | QoL-profile rarely/never discussed with CP (%) ( | |||
|---|---|---|---|---|---|---|
| The discussion of the QoL-profile with the CP was helpful | 83 | 0 | 78 | 8 | ||
| The QoL-profile comprises all dimensions that were relevant for me during the last months | 66 | 70 | .56 | 94 | 33 | |
| My other needs (e.g., pain, sorrows, anxiety) were also treated in addition to the diagnosis of breast cancer | 72 | 30 | 94 | 25 | ||
| My physicians and therapists found the right treatment strategy for my other needs | 69 | 40 | .23 | 89 | 17 | |
| I was regularly asked about my wellbeing | 72 | 50 | .25 | 83 | 50 | .10 |
| My wellbeing and QoL were more often discussed during the medical appointment | 55 | 20 | .07 | 61 | 8 | |
| The communication with my CP has improved | 24 | 0 | .16 | 28 | 8 | .36 |
| The relationship with my CP has improved | 24 | 0 | .16 | 33 | 17 | .42 |
| Other benefits | 21 | 0 | .31 | 22 | 0 | .13 |
| No benefit | 14 | 60 | 6 | 77 | ||
| The completion of the QoL questionnaire was burdensome | 3 | 10 | .45 | 6 | 0 | 1.0 |
aAll p values derived from χ2 tests or Fisher’s exacts test if smallest expected cell value was < 5
p values < 0.05 are presented in bold face